51
|
Kuwahara H, Song J, Shimoura T, Yoshida-Tanaka K, Mizuno T, Mochizuki T, Nishina K, Nagata T, Kusuhara H, Yokota T. Heteroduplex oligonucleotide as a platform technology to modulate blood-brain barrier function in vivo. J Neurol Sci 2017. [DOI: 10.1016/j.jns.2017.08.417] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
52
|
Igarashi S, Otani T, Takahashi Y, Soga K, Irioka T, Yokota T. Clinical features of two cases of deafness related to antineutrophil cytoplasmic antibodies-associated vasculitis. J Neurol Sci 2017. [DOI: 10.1016/j.jns.2017.08.3731] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
53
|
Li F, Ishibashi S, Iwasawa E, Song J, Ichijo M, Zhang Y, Piao W, Yoshida K, Yoshioka K, Kuwahara H, Nagata T, Yokota T. Gene silencing effect of heteroduplex oligonucleotide and its biodistribution in neurons and brain endothelial cells after ischemia. J Neurol Sci 2017. [DOI: 10.1016/j.jns.2017.08.2483] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
54
|
Takahashi Y, Soga K, Igarashi S, Otani T, Irioka T, Kaneko K, Takahashi T, Nakashima I, Yokota T. Two cases of anti-myelin oligodendrocyte glycoprotein-IGG positive optic neuritis with different courses. J Neurol Sci 2017. [DOI: 10.1016/j.jns.2017.08.3010] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
55
|
Onoue H, Murakami K, Yoshizawa K, Yokota T, Norimine S, Akaiwa Y, Kamiya F, Ogawa T, Kamiya T, Hara M, Takiguchi Y, Numahata K, Yamaguchi Y, Tamura N, Miyamoto T. Successful amyotrophic lateral sclerosis treated with edaravone circle support network building from Dokkyo Medical University Koshigaya hospital (Successful allstar net from DMUK). J Neurol Sci 2017. [DOI: 10.1016/j.jns.2017.08.1994] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
56
|
Nagata T, Ohyagi M, Ihara K, Kaburagi H, Nishina K, Piao W, Yoshida-Tanaka K, Kuwahara H, Yoshioka K, Yokota T. The effect of DNA/RNA heteroduplex oligonucleotides on muscle. J Neurol Sci 2017. [DOI: 10.1016/j.jns.2017.08.2383] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
57
|
Soga K, Igarashi S, Otani T, Takahashi Y, Irioka T, Yokota T. Clinical characteristics of four cases of Crowned Dens syndrome. J Neurol Sci 2017. [DOI: 10.1016/j.jns.2017.08.2658] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
58
|
Sato M, Miyazaki D, Shiba Y, Echigoya Y, Yokota T, Aoki Y, Takeda S, Nakamura A. The exon 45 skipping therapy of induced pluripotent stem cells derived cardiomyocyte from the DMD patient with exon 46-55 deletion. J Neurol Sci 2017. [DOI: 10.1016/j.jns.2017.08.420] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
59
|
Ono D, Ishibashi S, Yokota T. Paraspinal muscle density on computed tomography decreases in amyotrophic lateral sclerosis. J Neurol Sci 2017. [DOI: 10.1016/j.jns.2017.08.2283] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
60
|
Ichijo M, Ishibashi S, Miki K, Itaya S, Amino T, Kamata T, Yokota T. Significance of hyperintense vessels in negative DWI area as a prognostic factor after thrombolysis. J Neurol Sci 2017. [DOI: 10.1016/j.jns.2017.08.3672] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
61
|
Sato N, Yokota T, Mizusawa H, Ishikawa K. Pentanucleotide-repeat-associated unconventional translation is observed in spinocerebellar ataxia type 31. J Neurol Sci 2017. [DOI: 10.1016/j.jns.2017.08.2515] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
62
|
Matsuda T, Suzuki M, Kanazawa T, Tanaka H, Yokota T, Takei T. Clinical impact of ventriculitis detected by magnetic resonance imaging in bacterial meningitis in adults. J Neurol Sci 2017. [DOI: 10.1016/j.jns.2017.08.2855] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
63
|
Higashi M, Ozaki K, Hattori T, Ishii T, Soga K, Sato N, Tomita M, Mizusawa H, Ishikawa K, Yokota T. Cerebellar ataxia subgroups can be differentiated by pontine magnetic resonance imaging. J Neurol Sci 2017. [DOI: 10.1016/j.jns.2017.08.865] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
64
|
Irioka T, Igrarashi S, Takahashi Y, Otani T, Soga K, Yokota T. Dementia with Lewy bodies as a cause of acute alterations of consciousness in elderly patients visiting the emergency department. J Neurol Sci 2017. [DOI: 10.1016/j.jns.2017.08.1864] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
65
|
Miyazaki D, Sato M, Shiba Y, Echigoya Y, Yokota T, Aoki Y, Takeda S, Nakamura A. Dystrophin-deficient cardiomyocyte derived from Duchenne Muscular Dystrophy specific induced pluripotent stem cells carrying the deletion of exon 46-55 in DMD gene. J Neurol Sci 2017. [DOI: 10.1016/j.jns.2017.08.2421] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
66
|
Kanai K, Yokota T, Shibuya K, Nakazato T, Kanouchi T, Iwai Y, Oyama G, Shimo Y, Shimizu T, Hattori N, Kuwabara S. Increased motor axonal persistent sodium currents is associated with rapid regional spreading in amyotrophic lateral sclerosis. J Neurol Sci 2017. [DOI: 10.1016/j.jns.2017.08.3779] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
67
|
Ishiguro T, Sato N, Ueyama M, Fujikake N, Sellier C, Tokuda E, Zamiri B, Gall-Duncan T, Mirceta M, Furukawa Y, Yokota T, Wada K, Taylor P, Pearson C, Charlet-Berguerand N, Mizusawa H, Nagai Y, Ishikawa K. Balance between RNA binding proetin TDP-43 and an RNA UGGAA repeat underlies pathogenesis of spinocerebellar ataxia type 31 (SCA31) and motor neuron disease fly models. J Neurol Sci 2017. [DOI: 10.1016/j.jns.2017.08.218] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
68
|
Yokote H, Kamata T, Toru S, Sanjo N, Yokota T. Serum retinol levels are associated with brain volume loss in patients with multiple sclerosis. Mult Scler J Exp Transl Clin 2017; 3:2055217317729688. [PMID: 28932409 PMCID: PMC5598802 DOI: 10.1177/2055217317729688] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/17/2017] [Accepted: 08/13/2017] [Indexed: 11/24/2022] Open
Abstract
Background Although predicting future brain volume loss (BVL) in patients with multiple sclerosis (MS) is important, studies have shown only a few biomarkers that can predict BVL. Objectives The aim of this study is to elucidate the association between longitudinal BVL and serum biomarker candidates. Methods This single-center, retrospective, observational study intended to cover MS patients during January 2008 to March 2016. Patients who underwent brain MRI two times at intervals of >24 months and had a blood test to measure biomarker candidates at the time or within three months of the MRI scan were included. Evaluation of brain volume was performed by using SIENAX and SIENA in the FMRIB software library. Results Twenty-three patients with MS were included in this study. We found that serum retinol binding protein (RBP) levels were significantly correlated with percentage brain volume change (PBVC) (p = 0.0079). Furthermore, best subset selection of multiple linear regression models identified baseline normalized brain volume and serum RBP as the best predictors of PBVC. Conclusions Our study shows that lower serum retinol levels are associated with greater longitudinal BVL and that serum RBP and can be a predictor of BVL.
Collapse
|
69
|
Yokota T, Hamauchi S, Yoshida Y, Yurikusa T, Suzuki M, Yamashita A, Ogawa H, Onoe T, Mori K, Onitsuka T. The phase II study of HMB/Arg/Gln against oral mucositis induced by chemoradiotherapy for head and neck cancer patients. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx374.051] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
70
|
Nakajima T, Yokota T, Shingu Y, Yamada A, Iba Y, Ujihara K, Takada S, Shirakawa R, Furihata T, Tsuda M, Matsumoto J, Fukushima A, Matsui Y, Kinugawa S. P700Mitochondrial dysfunction in epicardial adipose tissue; possible role in progression of coronary artery disease. Eur Heart J 2017. [DOI: 10.1093/eurheartj/ehx501.p700] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
71
|
Sudo K, Matsumoto Y, Matsushima M, Konno K, Shimotohno K, Shigeta S, Yokota T. Novel Hepatitis C virus Protease Inhibitors: 2,4,6-Trihydroxy,3-Nitro-Benzamide Derivatives. ACTA ACUST UNITED AC 2017. [DOI: 10.1177/095632029700800608] [Citation(s) in RCA: 23] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
72
|
Yokota T, Ogawa T, Takahashi S, Okami K, Fujii T, Tanaka K, Iwae S, Ota I, Ueda T, Monden N, Matsuura K, Kojima H, Ueda S, Sasaki K, Fujimoto Y, Hasegawa Y, Beppu T, Nishimori H, Hirano S, Naka Y, Matsushima Y, Fujii M, Tahara M. Efficacy and safety of rebamipide liquid for chemoradiotherapy-induced oral mucositis in patients with head and neck cancer: a multicenter, randomized, double-blind, placebo-controlled, parallel-group phase II study. BMC Cancer 2017; 17:314. [PMID: 28476132 PMCID: PMC5420134 DOI: 10.1186/s12885-017-3295-4] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/10/2016] [Accepted: 04/24/2017] [Indexed: 01/12/2023] Open
Abstract
BACKGROUND Recent preclinical and phase I studies have reported that rebamipide decreased the severity of chemoradiotherapy-induced oral mucositis in patients with oral cancer. This placebo-controlled randomized phase II study assessed the clinical benefit of rebamipide in reducing the incidence of severe chemoradiotherapy-induced oral mucositis in patients with head and neck cancer (HNC). METHODS Patients aged 20-75 years with HNC who were scheduled to receive chemoradiotherapy were enrolled. Patients were randomized to receive rebamipide 2% liquid, rebamipide 4% liquid, or placebo. The primary endpoint was the incidence of grade ≥ 3 oral mucositis determined by clinical examination and assessed by central review according to the Common Terminology Criteria of Adverse Events version 3.0. Secondary endpoints were the time to onset of grade ≥ 3 oral mucositis and the incidence of functional impairment (grade ≥ 3) based on the evaluation by the Oral Mucositis Evaluation Committee. RESULTS From April 2014 to August 2015, 97 patients with HNC were enrolled, of whom 94 received treatment. The incidence of grade ≥ 3 oral mucositis was 29% and 25% in the rebamipide 2% and 4% groups, respectively, compared with 39% in the placebo group. The proportion of patients who did not develop grade ≥ 3 oral mucositis by day 50 of treatment was 57.9% in the placebo group, whereas the proportion was 68.0% in the rebamipide 2% group and 71.3% in the rebamipide 4% group. The incidences of adverse events potentially related to the study drug were 16%, 26%, and 13% in the placebo, rebamipide 2%, and rebamipide 4% groups, respectively. There was no significant difference in treatment compliance among the groups. CONCLUSIONS The present phase II study suggests that mouth washing with rebamipide may be effective and safe for patients with HNC receiving chemoradiotherapy, and 4% liquid is the optimal dose of rebamipide. TRIAL REGISTRATION ClinicalTrials.gov under the identifier NCT02085460 (the date of trial registration: March 11, 2014).
Collapse
|
73
|
van Westering T, Johansson H, Coenen-Stass A, Tanihata J, Takeda S, Yokota T, Lehtiö J, Wood M, El Andaloussi S, Roberts T, Aoki Y. Age-related and mutation-independent proteomic changes in dystrophic mouse muscle. Neuromuscul Disord 2017. [DOI: 10.1016/s0960-8966(17)30231-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
74
|
Matsuda S, Tsubosa Y, Sato H, Takebayashi K, Kawamorita K, Mori K, Niihara M, Tsushima T, Yokota T, Onozawa Y, Yasui H, Takeuchi H, Kitagawa Y. Comparison of neoadjuvant chemotherapy versus upfront surgery with or without chemotherapy for patients with clinical stage III esophageal squamous cell carcinoma. Dis Esophagus 2017; 30:1-8. [PMID: 26919154 DOI: 10.1111/dote.12473] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Abstract
Neoadjuvant chemotherapy (NAC) and chemoradiotherapy have been shown to extend postoperative survival, and preoperative therapy followed by esophagectomy has become the standard treatment worldwide for patients with esophageal squamous cell carcinoma (ESCC). The Japan Clinical Oncology Group 9907 study showed that NAC significantly extended survival in advanced ESCC, but the survival benefit for patients with clinical stage III disease remains to be elucidated. We compared the survival rates of NAC and upfront surgery in patients with clinical stage III ESCC. Consecutive patients histologically diagnosed as clinical stage III (excluding cT4) ESCC were eligible for this retrospective study. Between September 2002 and April 2007, upfront transthoracic esophagectomy was performed initially and, for patients with positive lymph node (LN) metastasis in a resected specimen, adjuvant chemotherapy using cisplatin and 5-fluororouracil every 3 weeks for two cycles was administered (Upfront surgery group). Since May 2007, a NAC regimen used as adjuvant chemotherapy followed by transthoracic esophagectomy has been administered as the standard treatment in our institution (NAC group). Patient characteristics, clinicopathological factors, treatment outcomes, post-treatment recurrence, and overall survival (OS) were compared between the NAC and upfront surgery groups. Fifty-one and 55 patients were included in the NAC and upfront surgery groups, respectively. The R0 resection rate was significantly lower in the NAC group than in the upfront surgery group (upfront surgery, 98%; NAC, 76%; P = 0.003). In the upfront surgery group, of 49 patients who underwent R0 resection and pathologically positive for LN metastasis, 22 (45%) received adjuvant chemotherapy. In the NAC group, 49 (96%) of 51 patients completed two cycles of NAC. In survival analysis, no significant difference in OS was observed between the NAC and upfront surgery groups (NAC: 5-year OS, 43.8%; upfront surgery: 5-year overall surgery, 57.5%; P = 0.167). Patients who underwent R0 resection showed significantly longer OS than did those who underwent R1, R2, or no resection (P = 0.001). In multivariate analysis using age, perioperative chemotherapy, depth of invasion, LN metastasis, surgical radicality, postoperative pneumonia, and anastomotic leakage as covariates, LN metastasis [cN2: hazard ratio (HR), 1.389; P = 0.309; cN3: HR, 16.019; P = 0.012] and surgical radicality (R1: HR, 3.949; P = 0.009; R2 or no resection: HR, 2.912; P = 0.022) were shown to be significant independent prognostic factors. In clinical stage III ESCC patients, no significant difference in OS was observed between NAC and upfront surgery. Although potential patient selection bias might be a factor in this retrospective analysis, the noncurative resection rate was higher after NAC than after upfront surgery. The survival benefit of more intensive NAC needs to be further evaluated.
Collapse
|
75
|
Hasegawa Y, Kiyota N, Takahashi S, Yokota T, Yen CJ, Iwae S, Shimizu Y, Hong RL, Goto M, Namba Y, Ferris R, Monga M, Lynch M, Hagihara S, Tahara M. 360O_PR Efficacy and safety of nivolumab for recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN) in Asia: CheckMate 141 subgroup analysis. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw587.002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|